On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above.

The EC’s Decision followed the positive opinion received from the EMA in November, 2020. This marks the first innovation in mechanism of action for an influenza antiviral approved by the EC in almost 20 years.